Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
HBM Holdings FCF Yield % Related Terms
HBM Holdings FCF Yield % Historical Data
* Premium members only.
The historical data trend for HBM Holdings's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02142 vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, HBM Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where HBM Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HKSE:02142) has a FCF Yield % of 5.59 as of Jul. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HBM Holdings and its competitors. According to the industry distribution chart, HBM Holdings ranks #83 out of 1409 companies in the Biotechnology industry, placing it in the top 5.9%.
Is HBM Holdings' FCF Yield % too high?
HBM Holdings' current FCF Yield % is 5.59. Based on the distribution chart, HBM Holdings ranks #83 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #83 out of 1409 companies for FCF Yield %. This places HBM Holdings in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HBM Holdings and its competitors. HBM Holdings's current FCF Yield % is 5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (HKSE:02142) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$7.03, compared to a current price of HK$11.69 — trading 66.3% above its estimated fair value. The current FCF Yield % is 5.59. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For HBM Holdings (HKSE:02142), the current FCF Yield % is 5.59 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HKSE:02142) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of HK$11.69 is trading 66.3% above its estimated GF Value™ of HK$7.03.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:02142:
FCF Yield %: 5.59
GF Value™: HK$7.03 vs. price of HK$11.69 (66.3% above fair value)
No single metric tells the full story. See the HKSE:02142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HKSE:02142
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02142 has been successfully added to your 
